功能成像筛查后不确定性甲状腺结节射频消融的中期结局
本研究回顾性纳入109例经功能成像评估后行射频消融的Bethesda III或IV类甲状腺结节患者,中位随访2.2年。主要终点局部治疗失败发生率为13.8%,3年无失败概率为85.4%。较大初始结节直径与失败风险增高及完全消失概率降低独立相关,结节<3 cm者预后更佳。
要点
- 初始最大径<3.0 cm的结节3年无局部治疗失败率达93%。
- 初始最大径>2.1 cm的结节未见完全消失。
- 初始最大径每增加1 cm,局部治疗失败风险增加2.35倍。
核心结论
- 在功能成像筛查后的不确定性甲状腺结节患者中,射频消融可获得可接受的局部控制与症状缓解,尤其适用于初始最大径<3 cm的结节。
研究设计与样本
- 所有患者均经功能成像评估后接受射频消融,中位随访2.2年(范围0.7–6.8年)。
- 参考标准为随访中结节再生长、活性体积增加或重复细胞学仍为不确定性。
关键影像表现/征象
- 射频消融后可见结节体积显著缩小,15例(13.8%)出现结节再生长或活性体积增加。
- 9例(8.3%)在随访期间实现结节完全消失。
- 结节初始最大径>2.1 cm者未观察到完全消失。
诊断标准与关键数值
- 3年无局部治疗失败概率为85.4%,3年完全消失累积发生率为6.5%。
- 初始最大径每增加1 cm,局部治疗失败风险HR为2.35(95%CI 1.23–4.48,P=0.010)。
- 初始最大径每增加1 cm,完全消失可能性HR为0.16(95%CI 0.04–0.60,P=0.006)。
- 3年时初始最大径<3.0 cm者93%无局部治疗失败,>2.1 cm者无一完全消失。
- 消融后症状评分、美容评分、游离T4及甲状腺球蛋白水平均显著下降。
临床应用与阅片要点
- 对不确定性甲状腺结节行射频消融前应测量初始最大径,<3 cm者预期局部控制较好。
- 初始最大径>2.1 cm者不应预期结节完全消失,需与患者充分沟通预期。
- 功能成像筛查后的Bethesda III或IV类结节可考虑射频消融作为替代方案。
局限性
- 回顾性队列研究设计本身存在选择偏倚与信息偏倚可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Current guidelines recommend surveillance or diagnostic lobectomy for indeterminate thyroid nodules. Although radiofrequency ablation (RFA) has emerged as a potential alternative, its role remains controversial. Functional imaging modalities, including 99mTc-methoxyisobutylisonitrile scintigraphy and ¹⁸F-fluorodeoxyglucose positron emission tomography, have been used to support risk stratification. This study evaluated the mid-term outcomes of RFA and their predictors in a functionally screened cohort of patients with indeterminate thyroid nodules.
MATERIALS AND METHODS: This retrospective cohort study included 109 patients with Bethesda category III or IV thyroid nodules who underwent RFA after functional imaging-based evaluation between January 2018 and November 2024. The primary outcome was local treatment failure (LTF), defined as the first occurrence of nodule regrowth, an increase in vital volume, or repeated indeterminate cytology. The secondary outcome was complete disappearance of the nodule. Supplementary outcomes included the volume reduction rate, symptom and cosmetic scores, and biochemical markers.
RESULTS: During a median follow-up of 2.2 years (range, 0.7-6.8 years), LTF occurred in 15 of 109 patients (13.8%), whereas complete disappearance was observed in 9 (8.3%) patients. The 3-year LTF-free probability and cumulative incidence of complete disappearance were 85.4% and 6.5%, respectively. Significant reductions were observed in the nodule volume, symptom scores, cosmetic scores, and free T4 and thyroglobulin levels. A greater initial maximum nodule diameter was independently associated with a higher likelihood of LTF (hazard ratio [HR] per 1-cm increase, 2.35; 95% confidence interval [CI], 1.23-4.48; P = 0.010) and a lower likelihood of complete disappearance (HR, 0.16; 95% CI, 0.04-0.60; P = 0.006). At 3 years, 93% of the tumors with an initial diameter <3.0 cm remained free of LTF, whereas no tumors >2.1 cm achieved complete disappearance.
CONCLUSION: In this functionally screened cohort of patients with indeterminate thyroid nodules, RFA demonstrated acceptable outcomes with volume reduction and symptom relief, particularly in patients with nodules <3 cm.
引用
- Shih, Lin, Chang, et al. Mid-Term Outcomes and Outcome Predictors after Radiofrequency Ablation for Indeterminate Thyroid Nodules Following Functional Imaging Screening: A Retrospective Cohort Study. Korean J Radiol. 2026. PMID: 42225577. doi:10.3348/kjr.2025.1883
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。